Literature DB >> 23007844

Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Sara Proietti1, Alessandra Cucina, Russel J Reiter, Mariano Bizzarri.   

Abstract

Melatonin is involved in many physiological functions and it plays an important role in many pathological processes as well. Melatonin has been shown to reduce the incidence of experimentally induced cancers and can significantly inhibit the growth of some human tumors, namely hormone-dependent cancers. The anticancer effects of melatonin have been observed in breast cancer, both in in vivo with models of chemically induced rat mammary tumors, and in vitro studies on human breast cancer cell lines. Melatonin acts at different physiological levels and its antitumoral properties are supported by a set of complex, different mechanisms of action, involving apoptosis activation, inhibition of proliferation, and cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007844     DOI: 10.1007/s00018-012-1161-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  246 in total

1.  Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects.

Authors:  Ignacio Bejarano; Javier Espino; Carmen Barriga; Russel J Reiter; José A Pariente; Ana B Rodríguez
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-01       Impact factor: 4.080

2.  Antiproliferative effects of melatonin on the growth of rat pituitary prolactin-secreting tumor cells in vitro.

Authors:  Quan-Hui Yang; Jian-Ning Xu; Rong-Kun Xu; Shiu-Fun Pang
Journal:  J Pineal Res       Date:  2007-03       Impact factor: 13.007

3.  Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line.

Authors:  Ahmet Korkmaz; Hiroshi Tamura; Lucien C Manchester; Gary B Ogden; Dun-Xian Tan; Russel J Reiter
Journal:  J Pineal Res       Date:  2008-09-16       Impact factor: 13.007

4.  Involvement of the mt1 melatonin receptor in human breast cancer.

Authors:  P T Ram; J Dai; L Yuan; C Dong; T L Kiefer; L Lai; S M Hill
Journal:  Cancer Lett       Date:  2002-05-28       Impact factor: 8.679

5.  Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.

Authors:  Ulkan Kilic; Bayram Yilmaz; Milas Ugur; Adnan Yüksel; Russel J Reiter; Dirk M Hermann; Ertugrul Kilic
Journal:  J Pineal Res       Date:  2011-09-14       Impact factor: 13.007

6.  Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions.

Authors:  Silvia López-Burillo; Dun-Xian Tan; Juan C Mayo; Rosa M Sainz; Lucien C Manchester; Russel J Reiter
Journal:  J Pineal Res       Date:  2003-05       Impact factor: 13.007

7.  HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.

Authors:  Kotha Subbaramaiah; Louise R Howe; Elisa R Port; Edi Brogi; Jack Fishman; Catherine H Liu; Timothy Hla; Clifford Hudis; Andrew J Dannenberg
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

8.  Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro.

Authors:  Mercedes M Leon-Blanco; Juan M Guerrero; Russel J Reiter; Juan R Calvo; David Pozo
Journal:  J Pineal Res       Date:  2003-10       Impact factor: 13.007

9.  Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin.

Authors:  Beatriz del Río; Juana M García Pedrero; Carlos Martínez-Campa; Pedro Zuazua; Pedro S Lazo; Sofía Ramos
Journal:  J Biol Chem       Date:  2004-06-30       Impact factor: 5.157

Review 10.  Light at night, chronodisruption, melatonin suppression, and cancer risk: a review.

Authors:  Russel J Reiter; Dun-Xian Tan; Ahmet Korkmaz; Thomas C Erren; Claus Piekarski; Hiroshi Tamura; Lucien C Manchester
Journal:  Crit Rev Oncog       Date:  2007-12
View more
  20 in total

1.  Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.

Authors:  Thaiz Ferraz Borin; Ali Syed Arbab; Gabriela Bottaro Gelaleti; Lívia Carvalho Ferreira; Marina Gobbe Moschetta; Bruna Victorasso Jardim-Perassi; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Verena Benedick Coimbra; Vanessa Alves Fabri; Juliana Garcia de Oliveira; Debora Aparecida Pires de Campos Zuccari
Journal:  J Pineal Res       Date:  2015-10-20       Impact factor: 13.007

Review 2.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

3.  Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.

Authors:  Elizabeth E Devore; Erica T Warner; A Heather Eliassen; Susan B Brown; Andrew H Beck; Susan E Hankinson; Eva S Schernhammer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-11-09       Impact factor: 4.254

Review 4.  Expression and putative functions of melatonin receptors in malignant cells and tissues.

Authors:  Cem Ekmekcioglu
Journal:  Wien Med Wochenschr       Date:  2014-07-15

5.  Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II.

Authors:  Susan B Brown; Susan E Hankinson; A Heather Eliassen; Katherine W Reeves; Jing Qian; Kathleen F Arcaro; Lani R Wegrzyn; Walter C Willett; Eva S Schernhammer
Journal:  Am J Epidemiol       Date:  2015-01-13       Impact factor: 4.897

Review 6.  Melatonin, mitochondria, and the cancer cell.

Authors:  Sara Proietti; Alessandra Cucina; Mirko Minini; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2017-08-07       Impact factor: 9.261

7.  Melatonin activity and receptor expression in endometrial tissue and endometriosis.

Authors:  A A Mosher; M W Tsoulis; J Lim; C Tan; S K Agarwal; N A Leyland; W G Foster
Journal:  Hum Reprod       Date:  2019-07-08       Impact factor: 6.918

8.  CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells.

Authors:  Wootae Kim; Joo-Won Jeong; Ja-Eun Kim
Journal:  Tumour Biol       Date:  2014-08-02

9.  Urinary levels of melatonin and risk of postmenopausal breast cancer: women's health initiative observational cohort.

Authors:  Susan R Sturgeon; Ashley Doherty; Katherine W Reeves; Carol Bigelow; Frank Z Stanczyk; Judith K Ockene; Simin Liu; JoAnn E Manson; Marian L Neuhouser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-07       Impact factor: 4.254

Review 10.  Peripheral reproductive organ health and melatonin: ready for prime time.

Authors:  Russel J Reiter; Sergio A Rosales-Corral; Lucien C Manchester; Dun-Xian Tan
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.